Key facts
- QNRX - Quoin Pharmaceuticals, Ltd. has 10 insiders with reported activity on this page.
- Net insider value flow over the last year: +$128,640.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 10 Insiders of Quoin Pharmaceuticals, Ltd.
- Symbol
- QNRX on Nasdaq
- Location
- Kfar Saba
Change
- Buy value: $128,640; sell value: $0.
- Net share flow: +15,152.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$128,640.
Buys
$128,640
Shares: 15,152
Insiders: 1
Sells
$0
Shares: 0
Insiders: 0
Net
+$128,640
Shares: +15,152
Insiders: 1
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 15,152 | 0 | $128,640 | $0 | +$128,640 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Quoin Pharmaceuticals, Ltd. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 10%+ Owner | $47,201,973 | Mixed | 26 Mar 2026 | ||
| Dennis Langer | Director | $128,648 | +$128,640 | +1608000% | Filing P/S | 04 Feb 2026 |
| Gordon Dunn | Chief Financial Officer | $67,985 | Filing P/S | 23 Dec 2024 | ||
| Sember Michael T. | Director | Mixed | 04 Feb 2026 | |||
| Natalie Ee Mun Leong | Director | Mixed | 04 Feb 2026 | |||
| Joseph Patrick Cooper | Director | Mixed | 04 Feb 2026 | |||
| Anthony James Culverwell | Director | Mixed | 04 Feb 2026 | |||
| Michael Myers | Chief Executive Officer, Director | Mixed | 04 Feb 2026 | |||
| Denise P. Carter | Chief Operating Officer, Director | Mixed | 04 Feb 2026 | |||
| Sally Bridget Lawlor | Chief Financial Officer | Mixed | 04 Feb 2026 |
Top shareholders of Quoin Pharmaceuticals, Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Ikarian Capital, LLC |
13D/G
13F
|
Company |
13%
|
211,538
|
$3,052,472 | $0 | 31 Jan 2026 | |
| Stonepine Capital Management, LLC |
3/4/5
13D/G
13F
|
10%+ Owner · Company |
11%
from 13D/G
|
3,271,100
|
$47,201,973 | — | 26 Mar 2026 | |
| Woodline Partners LP |
13D/G
13F
|
Company |
9.5%
|
2,785,370
|
$38,298,838 | $0 | 31 Dec 2025 | |
| Resolute Capital Asset Partners LLC |
13D/G
|
— |
8.5%
|
50,000
|
$671,000 | $0 | 10 Oct 2025 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
1,081,183
|
$7,049,313 | $0 | 31 Mar 2025 | |
| ADAR1 Capital Management, LLC |
13D/G
|
ADAR1 Capital Management GP, LLC |
4.9%
|
102,883
|
$609,067 | +$264,346 | 31 Mar 2026 | |
| Denise P. Carter |
13D/G
3/4/5
|
Denise Carter · Chief Operating Officer, Director |
4.9%
|
939,238
|
$244,202 | +$82,374 | 27 Jan 2025 | |
| Michael Myers |
13D/G
3/4/5
|
Chief Executive Officer, Director |
4.9%
|
939,230
|
$244,200 | +$82,331 | 27 Jan 2025 | |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
|
— |
4.6%
|
2,618,595
|
$36,005,681 | +$9,858,888 | 31 Dec 2025 | |
| Aberdeen Group plc |
13F
13D/G
|
Company |
4.2%
from 13D/G
|
75,000
|
$495,000 | — | 31 Mar 2026 | |
| Dauntless Investment Group, LLC |
13F
|
Company |
9.4%
|
196,592
|
$1,297,507 | — | 31 Mar 2026 | |
| SummitTX Capital, L.P. |
13F
|
Company |
4.8%
|
100,300
|
$661,980 | — | 31 Mar 2026 | |
| Velan Capital Investment Management LP |
13F
|
Company |
4%
|
84,849
|
$560,003 | — | 31 Mar 2026 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
3.6%
|
76,247
|
$503,230 | — | 31 Mar 2026 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
3.5%
|
72,730
|
$480,018 | — | 31 Mar 2026 | |
| Centiva Capital, LP |
13F
|
Company |
2.9%
|
60,000
|
$396,000 | — | 31 Mar 2026 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
2.8%
|
59,838
|
$394,931 | — | 31 Mar 2026 | |
| AIGH Capital Management LLC |
13F
|
Company |
2.4%
|
51,000
|
$336,600 | — | 31 Mar 2026 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.5%
|
32,519
|
$214,625 | — | 31 Mar 2026 | |
| Birchview Capital, LP |
13F
|
Company |
0.95%
|
20,000
|
$132,000 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.19%
|
4,000
|
$26,400 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.12%
|
2,512
|
$16,579 | — | 31 Mar 2026 | |
| GAMMA Investing LLC |
13F
|
Company |
0.08%
|
1,720
|
$11,352 | — | 31 Mar 2026 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.07%
|
1,521
|
$10,033 | — | 31 Mar 2026 | |
| BARCLAYS PLC |
13F
|
Company |
0.06%
|
1,300
|
$8,580 | — | 31 Mar 2026 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
2
|
$13 | — | 31 Mar 2026 | |
| Dennis Langer |
3/4/5
|
Director |
—
mixed-class rows
|
97,470
mixed-class rows
|
$128,648 | +$128,640 | 04 Feb 2026 | |
| Gordon Dunn |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
734,513
mixed-class rows
|
$67,985 | — | 23 Dec 2024 | |
| Sally Bridget Lawlor |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
85,690
mixed-class rows
|
— | — | 04 Feb 2026 | |
| Anthony James Culverwell |
3/4/5
|
Director |
—
class O/S missing
|
21,709
|
— | — | 04 Feb 2026 | |
| Natalie Ee Mun Leong |
3/4/5
|
Director |
—
class O/S missing
|
12,211
|
— | — | 04 Feb 2026 | |
| Joseph Patrick Cooper |
3/4/5
|
Director |
—
class O/S missing
|
8,141
|
— | — | 04 Feb 2026 | |
| Sember Michael T. |
3/4/5
|
Director |
—
class O/S missing
|
8,141
|
— | — | 04 Feb 2026 |
Recent Insider Transactions by Companies or Individuals for Quoin Pharmaceuticals, Ltd.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Sally Bridget Lawlor | QNRX | Share Option (Right to Buy) | Award | 85,250 | 85,250 | 04 Feb 2026 | Direct | |||
| Joseph Patrick Cooper | QNRX | Share Option (Right to Buy) | Award | 8,141 | 8,141 | 04 Feb 2026 | Direct | |||
| Anthony James Culverwell | QNRX | Share Option (Right to Buy) | Award | 21,709 | 21,709 | 04 Feb 2026 | Direct | |||
| Michael Myers | QNRX | Share Option (Right to Buy) | Award | 318,750 | 318,750 | 04 Feb 2026 | Direct | |||
| Denise P. Carter | QNRX | Share Option (Right to Buy) | Award | 318,750 | 318,750 | 04 Feb 2026 | Direct | |||
| Dennis Langer | QNRX | Share Option (Right to Buy) | Award | 21,709 | 21,709 | 04 Feb 2026 | Direct | |||
| Sember Michael T. | QNRX | Share Option (Right to Buy) | Award | 8,141 | 8,141 | 04 Feb 2026 | Direct | |||
| Natalie Ee Mun Leong | QNRX | Share Option (Right to Buy) | Award | 12,211 | 12,211 | 04 Feb 2026 | Direct | |||
| Sally Bridget Lawlor | QNRX | Share Option (Right to Buy) | Award | 10,330 | 10,330 | 01 Dec 2025 | Direct | |||
| Dennis Langer | QNRX | ADSs | Purchase | 1515200% | $128,640 | $8.49 | 15,152 | 15,153 | 14 Oct 2025 | Direct |
| Dennis Langer | QNRX | Series K Warrants (Right to Buy) | Purchase | 15,152 | 15,152 | 14 Oct 2025 | Direct | |||
| Dennis Langer | QNRX | Series J Warrants (Right to Buy) | Purchase | 15,152 | 15,152 | 14 Oct 2025 | Direct | |||
| Dennis Langer | QNRX | Series I Warrants (Right to Buy) | Purchase | 15,152 | 15,152 | 14 Oct 2025 | Direct | |||
| Dennis Langer | QNRX | Series H Warrants (Right to Buy) | Purchase | 15,152 | 15,152 | 14 Oct 2025 | Direct | |||
| Natalie Ee Mun Leong | QNRX | Share Option (Right to Buy) | Award | 4,105 | 4,105 | 21 Aug 2025 | Direct | |||
| Anthony James Culverwell | QNRX | Share Option (Right to Buy) | Award | 13,682 | 13,682 | 21 Aug 2025 | Direct | |||
| Dennis Langer | QNRX | Share Option (Right to Buy) | Award | 13,682 | 13,682 | 21 Aug 2025 | Direct | |||
| Denise P. Carter | QNRX | Share Option (Right to Buy) | Award | 42,857 | 42,857 | 29 May 2025 | Direct | |||
| Michael Myers | QNRX | Share Option (Right to Buy) | Award | 42,857 | 42,857 | 29 May 2025 | Direct | |||
| Anthony James Culverwell | QNRX | Share Option (Right to Buy) | Award | 7,760 | 7,760 | 29 May 2025 | Direct | |||
| Natalie Ee Mun Leong | QNRX | Share Option (Right to Buy) | Award | 7,760 | 7,760 | 29 May 2025 | Direct | |||
| Dennis Langer | QNRX | Share Option (Right to Buy) | Award | 7,760 | 7,760 | 29 May 2025 | Direct | |||
| Joseph Patrick Cooper | QNRX | Share Option (Right to Buy) | Award | 7,760 | 7,760 | 29 May 2025 | Direct | |||
| Sember Michael T. | QNRX | Share Option (Right to Buy) | Award | 7,760 | 7,760 | 29 May 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.